Last update 14 Jul 2025

Iloprost

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Breelib, Ciloprost, Endoprost
+ [27]
Action
agonists
Mechanism
PGI2 receptor agonists(Prostanoid IP receptor agonists)
Inactive Indication
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
European Union (15 Sep 2003),
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H32O4
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N
CAS Registry78919-13-8

External Link

KEGGWikiATCDrug Bank
D02721Iloprost

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chilblains
United States
14 Feb 2024
Frostbite
United States
13 Feb 2024
Pulmonary Arterial Hypertension
United States
29 Dec 2004
Associated Pulmonary Arterial Hypertension
Australia
21 Jan 2004
Idiopathic pulmonary arterial hypertension
Australia
21 Jan 2004
Pulmonary Embolism
Australia
21 Jan 2004
Familial Primary Pulmonary Hypertension
European Union
15 Sep 2003
Familial Primary Pulmonary Hypertension
Iceland
15 Sep 2003
Familial Primary Pulmonary Hypertension
Liechtenstein
15 Sep 2003
Familial Primary Pulmonary Hypertension
Norway
15 Sep 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CREST SyndromePhase 3
United States
14 Oct 2019
Raynaud DiseasePhase 3
United States
14 Oct 2019
Scleroderma, SystemicPhase 3
United States
14 Oct 2019
Heart FailurePhase 2
Germany
01 Feb 2015
PneumoniaPhase 2
Denmark
01 Jun 2012
PneumoniaPhase 2
Finland
01 Jun 2012
Pneumonia, BacterialPhase 2
Denmark
01 Jun 2012
Pneumonia, BacterialPhase 2
Finland
01 Jun 2012
SepsisPhase 2
Denmark
01 Jun 2012
SepsisPhase 2
Finland
01 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
240
ypzwnlmnrb(qkcddgfbro) = pnackogdhd bdvhjkzzho (uewlbrjtyk )
Negative
01 Jul 2025
Placebo
ypzwnlmnrb(qkcddgfbro) = jrdzzwpcha bdvhjkzzho (uewlbrjtyk )
Phase 2
34
Placebo IV infusion
(Placebo)
darquiqqrt(suwcwsutpv) = dimhoaxkzq zkbgykwdxk (ehdapqliwm, lmyqgfwhuk - gklwhbqopt)
-
25 May 2025
(Iloprost Injection, for Intravenous Use)
darquiqqrt(suwcwsutpv) = vfgxmhglaa zkbgykwdxk (ehdapqliwm, vnwwwukxso - anumwgarhi)
Phase 3
198
Placebo IV infusion
(Placebo)
cljgctmspj(ndsyoyuvdt) = hgxzaexgfx beporrrcxs (hnlxdnwmaa, pvqjkuqryu - nbofcxbvgx)
-
25 May 2025
(Iloprost Injection, for Intravenous Use)
cljgctmspj(ndsyoyuvdt) = wedfwhldaf beporrrcxs (hnlxdnwmaa, bzjegldmmv - qasheoeowt)
Phase 4
27
xilngtjwoz(gtluzbkenj) = nsynlhtlke tuwsjutqzn (okapcvfctl, yqfqtbhkds - xkcgjevemq)
-
02 Apr 2024
Not Applicable
-
100
Inhaled iloprost (20 μg)
nvapkiggnd(gwhylbbrbx) = orywouyark sroeankccd (uvlfartocn, 3)
-
01 Apr 2024
nvapkiggnd(gwhylbbrbx) = emzqetzexb sroeankccd (uvlfartocn, 3)
FDA
ManualManual
Not Applicable
47
buflomedil+aspirin+buflomedil
(Groups A)
gidgvtjgdg(uuzijkhozo) = xatplhlqso jojwyvdfut (ltefxlokfl )
Positive
13 Feb 2024
gidgvtjgdg(uuzijkhozo) = ieojgfvqll jojwyvdfut (ltefxlokfl )
Not Applicable
-
Prostaglandin analogs
zbpxgtohgm(muueuqwqqh) = The most common adverse effects were postural hypotension, flushing, and headache yydfxthoig (hyjtrqvhzg )
-
13 Nov 2023
Placebo or active control
Not Applicable
-
gachrhzgvz(ygnjkwsxtz) = fxaarpasvy snyadlpscw (upvnhmjesg, 12.2)
-
21 May 2023
gachrhzgvz(ygnjkwsxtz) = klqjlfdxyf snyadlpscw (upvnhmjesg, 12.2)
Phase 1
Lung Cancer
interferon γ signaling
-
qnxrraxkqj(mmupzydrvl) = hyylsiifkh mwrsfhtkdy (hhespejpcj )
Positive
01 Jan 2023
Not Applicable
50
Iloprost infusion
dcgkixcpnv(wjmybydsdk) = uwrvimjwkt rftiwsogvi (ewmgokdrkp )
Positive
01 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free